IRVINE, Calif.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that Richard Rubino, Chief Financial Officer, will present in a fireside chat discussion at the RBC Capital Markets 2016 Healthcare Conference on Tuesday, February 23, 2016 at 10:30 a.m. Eastern Time in New York, NY. Mr. Rubino will provide an Aerie overview and business update.
The fireside chat discussion will be webcast live and may be accessed by visiting Aerie's website at http://investors.aeriepharma.com/. A replay of the webcast will be available for 10 business days.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie recently reported the successful results of its second Phase 3 registration trial in the United States named Rocket 2, where the primary efficacy endpoint was to demonstrate non-inferiority of IOP lowering for Rhopressa™ compared to timolol. Rocket 3, a 12-month safety-only study, is currently in progress, as is a fourth Phase 3 trial for Rhopressa™, named Rocket 4. Aerie expects to file a new drug application for Rhopressa™ with the FDA in the third quarter of 2016. Aerie also completed in 2014 a Phase 2b clinical trial in which Roclatan™ met the primary efficacy endpoint, demonstrating the statistical superiority of Roclatan™ to each of its components, and commenced in September 2015 the first Phase 3 registration trial for Roclatan™, named Mercury 1. Aerie also recently entered into research collaborations with GrayBug, Inc. and Ramot at Tel Aviv University as it further builds its pipeline for future growth.